ALK and non-small cell lung carcinoma: Brigatinib, a newly developed next-generation ALK inhibitor that was launched in China recently also demonstrated better clinical efficacy than first-generation ALK inhibitors in first-line treatment for patients with advanced ALK-positive NSCLC.